Haemophilia and cancer: A personal perspective

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 26-31

  Franchini, Massimo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

Cancer; Haemophilia; Therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; THROMBIN; WARFARIN;

ADVANCED CANCER; ANTICOAGULANT THERAPY; BLEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; COMORBIDITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LUNG METASTASIS; LUNG SMALL CELL CANCER; MECHANICAL STRESS; MELANOMA CELL; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NEOPLASM; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZED MORTALITY RATIO; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE; THROMBOCYTOPENIA; TUMOR GROWTH; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS;

EID: 84872248683     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0149-11     Document Type: Review

References (42)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9. (Pubitemid 32497033)
2. Tagliaferri A, Rivolta GF, Iorio A, et al. Italian Association of Hemophilia Centers: Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
3. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
4. Franchini M, Tagliaferri A, Mannucci PM. The management of hemophilia in elderly patients. Clin Interv Aging 2007; 2: 361-8.
5. Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
6. Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010; 16 (Suppl. 5): 11-6.
7. Franchini M, Lippi G, Montagnana M, et al. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev 2009; 35: 374-7.
8. Dunn AL. Malignancy in patients with haemophilia: a review of the literature. Haemophilia 2010; 16: 427-36.
9. Miesbach W, Seifried E. Does hemophilia influence cancer-related mortality in HIV-negative patients? Haemophilia 2011; 17: 55-60.
10. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, ed. Clinique medicinale de l'Hotel-Dieu de Paris. Paris, France: JB Bailliere et fils; 1865. p. 645-712.
11. Hu L, Lee M, Campbell W, et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104: 2746-51. (Pubitemid 39434957)
12. Franchini M, Montagnana M, Targher G, et al. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24: 29-38. (Pubitemid 46831561)
13. Langer F, Amirkhosravi A, Ingersoll SB, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006; 4: 1056-62.
14. Bruggemann LW, Versteeg HH, Niers TM, et al. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Biol Med 2008; 12: 2622-7.
15. Dubé C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007; 146: 365-75. (Pubitemid 351650597)
16. Maurer LH, Herndon JE 2nd, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 3378-87. (Pubitemid 27485858)
17. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984; 53: 2046-52. (Pubitemid 14101772)
18. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9. (Pubitemid 24113632)
19. Thornes RD, Daly L, Lynch G, et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol 1994; 120 (Suppl): S32-4. (Pubitemid 24142552)
20. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. N Engl J Med 2000; 342: 1953-8. (Pubitemid 30419090)
21. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007; 8: 395-402. (Pubitemid 46621759)
22. Smorenburg SM, Vink R, Otten HM, et al. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586-7. (Pubitemid 34007540)
23. Akl EA, Kamath G, Kim SY, et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev 2007; 2: CD006466.
24. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007; 33: 358-68. (Pubitemid 46760529)
25. Smorenburg SM, Hettiarachchi RJ, Vink R, et al. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb Haemost 1999; 82: 1600-4.
26. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-71. (Pubitemid 40186120)
27. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8. (Pubitemid 41095187)
28. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5. (Pubitemid 46218704)
29. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729-37. (Pubitemid 46563571)
30. Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2011; 4: CD006652.
31. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-9. (Pubitemid 46218703)
32. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-61. (Pubitemid 47312882)
33. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350: 1425-31. (Pubitemid 28036863)
34. Ragni MV, Belle SH, Bass D, et al. Clinical characteristics and blood product usage in AIDS-associated lymphoma in haemophiliacs: a case-control study. Haemophilia 1998; 4: 826-35. (Pubitemid 28561375)
35. Plug I, van der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-6.
36. Ragni MV, Belle SH, Jaffe RA, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia. Blood 1993: 81: 1889-97. (Pubitemid 23101605)
37. Wilde JT, Lee CA, Darby SC, et al.; UK Haemophilia Centre Doctors' Organisation. The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS 2002; 16: 1803-7.
38. Walker IR, Julian JA. Association of Hemophilia Clinic Directors of Canada. Causes of death in Canadians with haemophilia 1980-1995. Haemophilia 1998; 4: 714-20. (Pubitemid 28442426)
39. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25. (Pubitemid 47267416)
40. Tagliaferri A, Di Perna C, Santoro C, et al; on behalf the Italian Association of Hemophilia Centers. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost 2012; 10: 90-5.
41. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42. (Pubitemid 30463360)
42. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-63.